2023.06.22
I-Mab Announces the Appointment of Raj Kannan as CEO
Mr. Raj Kannan joins the Company as Chief Executive Officer and a member of the board of directors.
2023.05.26
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
The Company reports encouraging clinical results of uliledlimab at the ASCO Annual Meeting.
2023.04.26
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
The Company will present a poster featuring the latest clinical data of uliledlimab in combination with PD-1 therapy in NSCLC at ASCO 2023.
2023.04.25
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute.
2023.04.24
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
The first patient in a Phase 3 registrational trial in China for patients with HR-MDS has been dosed with lemzoparlimab in combination with AZA.
2023.03.31
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022
The Company today announced its financial results for the 12 months ended December 31, 2022, and provided key business updates.
2023.03.20
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023
The Company announced date of reporting financial results for year 2022.
2023.03.13
I-Mab Confirms No Banking Relationship with Silicon Valley Bank
I-Mab today issued a statement on the recent developments of the SVB.
2023.03.07
I-Mab Receives “A” Rating in Updated MSCI ESG Assessment
I-Mab has been granted “A” rating by Morgan Stanley Capital International ESG.
2022.11.03
I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022
Two poster presentations featuring preclinical and translational research data of lemzoparlimab will be presented at the 2022 ASH Annual Meeting.